Naaem Simaan1,2, Jeremy Molad3, Asaf Honig4, Andrei Filioglo4, Fadi Shbat1,2, Eitan Auriel5,6, Rani Barnea5,6, Hen Hallevi3,6, Estelle Seyman4, Rom Mendel5,6, Ronen R Leker7, Shlomi Peretz5,6. 1. Department of Neurology, Ziv Medical Center, Safed, Israel. 2. The Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel. 3. Department of Stroke and Neurology, Sourasky medical center, Tel-Aviv, Israel. 4. Departments of Neurology, Hadassah-Hebrew University Medical Center, P.O. Box 12000, 91120, Jerusalem, Israel. 5. Department of Neurology, Rabin Medical Center, Petach Tikva, Israel. 6. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 7. Departments of Neurology, Hadassah-Hebrew University Medical Center, P.O. Box 12000, 91120, Jerusalem, Israel. leker@hadassah.org.il.
Abstract
OBJECTIVES: Janus kinase 2 (JAK2-V617F) mutations can cause thrombocytosis, polycythemia and hyper viscosity leading to cerebral sinus venous thrombosis (CSVT). However, data regarding the characteristics and prevalence of JAK2-V617F mutation in patients with CSVT are currently lacking. We aimed to evaluate the characteristics of CSVT patients that carry the JAK2 mutation. MATERIALS AND METHODS: Data of consecutive patients with CSVT, admitted to three large academic medical centers between 2010 and 2020, were retrospectively studied. Demographics, clinical presentations, radiological and clinical outcome parameters were compared between carriers of the JAK2-V617F mutation and controls. RESULTS: Out of 404 patients diagnosed with CSVT, 26 patients (6.5%) were carriers of the mutation. JAK2 mutation carriers more often had thrombocytosis (54% vs. 1%, p < 0.001). Furthermore, carriers of the JAK2 mutation less often had involvement of the transverse sinus (50% vs. 68%, p = 0.021). Finally, patients with the JAK2 mutation were more prone to have intracerebral hemorrhage (ICH, 31% vs. 17%, p = 0.044), but there was no significant difference between groups in terms of mortality nor functional outcome. CONCLUSIONS: JAK2 mutation is not uncommon in patients with CSVT and should be routinely screened for in this population. CSVT in JAK2 mutation carriers may have a tendency toward involving specific venous sinuses and is associated with a higher rate of ICH but similar overall prognosis.
OBJECTIVES: Janus kinase 2 (JAK2-V617F) mutations can cause thrombocytosis, polycythemia and hyper viscosity leading to cerebral sinus venous thrombosis (CSVT). However, data regarding the characteristics and prevalence of JAK2-V617F mutation in patients with CSVT are currently lacking. We aimed to evaluate the characteristics of CSVT patients that carry the JAK2 mutation. MATERIALS AND METHODS: Data of consecutive patients with CSVT, admitted to three large academic medical centers between 2010 and 2020, were retrospectively studied. Demographics, clinical presentations, radiological and clinical outcome parameters were compared between carriers of the JAK2-V617F mutation and controls. RESULTS: Out of 404 patients diagnosed with CSVT, 26 patients (6.5%) were carriers of the mutation. JAK2 mutation carriers more often had thrombocytosis (54% vs. 1%, p < 0.001). Furthermore, carriers of the JAK2 mutation less often had involvement of the transverse sinus (50% vs. 68%, p = 0.021). Finally, patients with the JAK2 mutation were more prone to have intracerebral hemorrhage (ICH, 31% vs. 17%, p = 0.044), but there was no significant difference between groups in terms of mortality nor functional outcome. CONCLUSIONS: JAK2 mutation is not uncommon in patients with CSVT and should be routinely screened for in this population. CSVT in JAK2 mutation carriers may have a tendency toward involving specific venous sinuses and is associated with a higher rate of ICH but similar overall prognosis.
Authors: K Afifi; G Bellanger; P J Buyck; S M Zuurbier; C G Esperon; M A Barboza; P Costa; I Escudero; D Renard; R Lemmens; N Hinteregger; F Fazekas; J Jimenez Conde; E Giralt-Steinhauer; S Hiltunen; A Arauz; A Pezzini; J Montaner; J Putaala; C Weimar; Marc Schlamann; T Gattringer; T Tatlisumak; J M Coutinho; P Demaerel; V Thijs Journal: J Neurol Date: 2020-06-22 Impact factor: 4.849
Authors: S M Passamonti; E Biguzzi; M Cazzola; F Franchi; F Gianniello; P Bucciarelli; D Pietra; P M Mannucci; I Martinelli Journal: J Thromb Haemost Date: 2012-06 Impact factor: 5.824
Authors: Matthias Lamy; Paola Palazzo; Pierre Agius; Jean Claude Chomel; Jonathan Ciron; Aline Berthomet; Paul Cantagrel; Julia Prigent; Pierre Ingrand; Mathieu Puyade; Jean-Philippe Neau Journal: Cerebrovasc Dis Date: 2017-06-14 Impact factor: 2.762
Authors: Jan J Michiels; Zwi Berneman; Dirk Van Bockstaele; Marc van der Planken; Hendrik De Raeve; Wilfried Schroyens Journal: Semin Thromb Hemost Date: 2006-04 Impact factor: 4.180